Dr. Yi Chen
Recent Articles
Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands 03/13/2026
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note.
Miami Biopharma Sells Part of Business and Begins New Clinical Trial 01/02/2025
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating.
Recent Quotes
"INO's Zika virus vaccine success further validates the SynCon platform; we reiterate our Buy rating."
—
Dr. Yi Chen, H.C. Wainwright & Co.
(2/18/16)
more >
